SCHEMBL6732239

SCHEMBL6732239

CCC(=O)N(Cc1ccncc1)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNF4 P78317 1/20 0.57
LTB4R2 Q9NPC1 4/20 0.48
MMP13 P45452 2/20 0.48
HTT P42858 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
LMNA P02545 2/20 0.48
CYP3A4 P08684 1/20 0.48
MAPK14 Q16539 1/20 0.48
NPY5R Q15761 1/20 0.46
NR3C1 P04150 1/20 0.46
GRM2 Q14416 1/20 0.46
ALDH1A1 P00352 2/20 0.43
NPC1 O15118 1/20 0.43
GLA P06280 1/20 0.43
RAB9A P51151 1/20 0.43
PAX8 Q06710 1/20 0.43
USP2 O75604 1/20 0.43
TSHR P16473 1/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6727472 0.87 RNF4 (0.53) RNF4LTB4R2MMP13HTTSMN1; SMN2
SCHEMBL6732704 0.86 GRM2 (0.63) RNF4LMNACYP3A4GRM2ALDH1A1
SCHEMBL6738591 0.85 RNF4 (0.54) RNF4MMP13HTTSMN1; SMN2LMNA
SCHEMBL6739479 0.84 NPY5R (0.51) RNF4LTB4R2MMP13HTTSMN1; SMN2
SCHEMBL6732007 0.82 HTT (0.49) RNF4MMP13HTTSMN1; SMN2LMNA
SCHEMBL6736436 0.81 MAPK14 (0.49) RNF4SMN1; SMN2MAPK14ALDH1A1KDM4E
SCHEMBL6727502 0.78 LMNA (0.53) RNF4MMP13HTTSMN1; SMN2LMNA
SCHEMBL5804310 0.77 ALDH1A1 (0.69) LTB4R2HTTSMN1; SMN2ALDH1A1NPC1
SCHEMBL23518793 0.77 RNF4 (0.85) RNF4HTTSMN1; SMN2NR3C1ALDH1A1
SCHEMBL1337080 0.76 USP2 (0.60) RNF4SMN1; SMN2LMNAALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040006114-A1 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-01-08 US claimed
EP-1255735-A2 PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2002-11-13 EP claimed
WO-2001056990-A2 PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2001-08-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006114-A1 Potentiators of glutamate receptors GRM1, GRIN1, GRM2 RNF4 4707/4885LTB4R2 486/4885MMP13 4756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.